Finally, our in vitro results indicate that among the BTK inhibitors RN486 is more powerful than Ibrutinib and AVL-292 in blocking lung cancer cell proliferation and sensitizing drug-resistant NSCLC cells to either EGFR-TKIs and SOC therapy. Here, BTK is linked to lung carcinoma.